GENE ONLINE|News &
Opinion
Blog

China Approves Avastin’s New Indication

by GeneOnline
Share To

As the world’s first anti-tumor angiogenesis treatment drug, Avastin was approved in China to treat colorectal cancer and non-small cell lung cancer ( NSCLC ) indications. On September 21, Roche announced that Avastin had been approved by the National Medical Products Administration (NMPA) of China to treat adult patients with recurrent glioblastoma (GBM).

Avastin is a humanized monoclonal antibody lgG1 developed by Roche. Avastin can bind to tumor Vascular Endothelial Growth Factor (VEGF) to not stimulate the growth of blood vessels. The blood, oxygen, and other nutrients required for tumor growth are blocked, preventing their growth or spreading to other parts of the body, and ultimately achieving anti-cancer effects.

Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults. In the West, the annual incidence or number of new diagnoses is 2 to 3 per 100,000 people. GBM accounts for 12% to 15% of all intracranial tumors and 50% to 60% of astrocytoma. GBM can invade and infiltrate the normal surrounding brain tissue extensively, making complete resection impossible. Even with comprehensive treatments such as surgery, radiotherapy and chemotherapy, GBM patients are still very prone to relapse and die of tumors quickly. GBM is considered being one of the most challenging tumors in neurosurgery.

This new indication’s approval is mainly based on a multi-center, open-label, randomized controlled, pivotal phase III clinical trial EORTC 26101. This study confirmed that compared with chemotherapy alone, Avastin-based treatment prolonged the time to progression-free survival or the time to death (median PFS: 4.2 months vs. 1.5 months, HR=0.52, 95%CI: 0.41-0.64), the risk of disease progression can be reduced by 51%. During the progression-free survival period, patients in remission showed more stable global health scores and cognitive functions than non-remission patients. This means that Avastin will bring new treatment options for Chinese GBM patients. The approval of Avastin this time fills up the gap in GBM treatment in China. It is of great significance to improving the level of GBM diagnosis and treatment in China and will bring good news to patients who lack effective treatment options.


Partner Article, By James Hou, Ph.D.

 

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Europe Okays Roche’s CAR-T Competitor for Blood Cancer
2022-06-09
First Oral SMA Drug by Roche Now Available to Newborns
2022-06-01
R&D
These Companies Are Harnessing Oncolytic Viruses to Target Cancer
2022-05-25
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top